Home > Insider Trading > Filing (0001567619-21-018677)

Filing Details

Accession Number:: 0001567619-21-018677
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-10-25 19:40:28
Reporting Period:: 2021-10-25

Accepted Time:: 2021-10-25 19:40:28
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1851194	Ventyx Biosciences Inc.	VTYX	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1278411	S Corey Goodman	1700 Owens Street Suite 595 San Francisco CA 94158	No	No	Yes	Yes
1329161	J Robert Adelman	1700 Owens Street Suite 595 San Francisco CA 94158	No	No	Yes	Yes
1739920	Venbio Global Strategic Fund Iii, L.p.	1700 Owens Street Suite 595 San Francisco CA 94158	No	No	Yes	Yes
1869300	Venbio Global Strategic Gp Iii, Ltd	1700 Owens Street Suite 595 San Francisco CA 94158	No	No	Yes	Yes
1869303	Venbio Global Strategic Gp Iii, L.p.	1700 Owens Street Suite 595 San Francisco CA 94158	No	No	Yes	Yes

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-10-25	3,684,769	$0.00	3,684,769	No	4	C	Direct
Common Stock	Acquisiton	2021-10-25	312,500	$16.00	3,997,269	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2021-10-25	3,289,742	$0.00	3,289,742	$0.00
Common Stock	Series B Preferred Stock	Disposition	2021-10-25	395,027	$0.00	395,027	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct
0			No	4	C	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	1,014,267	Indirect	See footnote

Footnotes

All shares of the preferred stock, par value $0.0001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The preferred stock had no expiration date.
Shares held by venBio SPV III, LLC ("venBio SPV"). venBio SPV is wholly owned and managed by venBio Global Strategic Fund III, L.P. ("venBio III"). venBio Global Strategic GP III, L.P., a Cayman Islands partnership ("venBio GP") is the sole general partner of venBio III. venBio Global Strategic GP III, Ltd., a Cayman Islands company ("venBio Ltd") is the sole general partner of venBio GP. Aaron Royston, Robert Adelman and Corey Goodman (collectively, the "Directors") are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the shares held by venBio SPV. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the shares held by venBio SPV except to the extent of their pecuniary interest therein.
Shares held by venBio III. venBio GP is the sole general partner of venBio III. venBio Ltd is the sole general partner of venBio GP. The Directors are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the shares held by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the shares held by venBio III except to the extent of their pecuniary interest therein.